首页> 外文OA文献 >Performance of research ethics committees in Spain. A prospective study of 100 applications for clinical trial protocols on medicines.
【2h】

Performance of research ethics committees in Spain. A prospective study of 100 applications for clinical trial protocols on medicines.

机译:西班牙研究道德委员会的表现。一项针对药物的临床试验方案的100项应用的前瞻性研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVES: To review the characteristics and performance of research ethics committees in Spain in the evaluation of multicentre clinical trial drug protocols. DESIGN: A prospective study of 100 applications. SETTING: Forty-one committees reviewing clinical trial protocols, involving 50 hospitals in 25 cities. MAIN MEASURES: Protocol-related features, characteristics of research ethics committees and evaluation dynamics. RESULTS: The 100 applications involved 15 protocols (of which 12 were multinational) with 12 drugs. Committees met monthly (except one). They had a mean number of 12 members, requested a mean of six complete dossiers and nine additional copies of the protocol with a mean deadline of 14 days before the meeting. All applications were approved except three (two of the three were open-label long-term safety trials rejected by the same committee), which were approved by the other committees involved. The mean time from submission to approval was 64 days. The mean time from submission to arrival of the approval document at our offices was 85 days. Twenty-five committees raised queries for 38 of the 97 finally approved applications. Impact of evaluation fee, number of members, queries raised and experience of committees on timings were not statistically significant. CONCLUSION: Obtaining ethical approval is time-consuming. There is much diversity in the research ethics committees' performance. A remarkable delay (> 20 days) exists between the decision and the arrival of the written approval, suggesting administrative or organisational problems.
机译:目的:回顾西班牙研究伦理委员会在评估多中心临床试验药物方案中的特征和表现。设计:对100个应用程序的前瞻性研究。地点:审查临床试验方案的41个委员会,涉及25个城市的50家医院。主要指标:与协议相关的特征,研究伦理委员会的特征和评估动态。结果:100份申请涉及15项协议(其中12项是跨国协议)和12种药物。委员会每月开会一次(一次除外)。他们的平均人数为12名,平均要求提供6份完整的档案和9份附加的议定书副本,平均截止日期为会议前14天。除三项(三项中的两项为同一委员会拒绝的开放式长期安全性试验)外,其他所有申请均获得批准。从提交到批准的平均时间为64天。从提交批准文件到到达我们办公室的平均时间为85天。 25个委员会对97个最终批准的申请中的38个提出了疑问。评估费,成员数量,提出的问题和委员会在时间安排上的经验的影响在统计上不显着。结论:获得道德认可很耗时。研究伦理委员会的表现各不相同。从做出决定到获得书面批准之间存在显着的延迟(> 20天),表明存在行政或组织问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号